Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant TP plus toripalimab followed by toripalimab with radiotherapy for laryngeal or hypopharyngeal carcinoma
ChiCTR2000033506Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, paclitaxel and cisplatin in laryngeal cancer and hypopharyngeal carcinoma (HPC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started Jun 2020; status: recruiting.
02
Drugs
toripalimabpaclitaxelcisplatin
03
Conditions
laryngeal cancerhypopharyngeal carcinoma (HPC)
Beyond the preview
Go deeper on ChiCTR2000033506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033506.